What's Happening?
The National Institute for Health and Care Excellence (NICE) in England and Wales has proposed to cease funding for Amgen's lung cancer drug Lumykras. The decision is based on limitations in clinical evidence and uncertainties in the economic model, including
the long-term benefits of the drug. Lumykras, used for treating KRAS G12C mutation-positive non-small-cell lung cancer, has been funded by the Cancer Drugs Fund since 2022. Amgen has expressed disappointment, arguing that the decision does not reflect real-world evidence and the drug's impact on patients with limited treatment options.
Why It's Important?
The proposed funding cut for Lumykras could significantly impact patients with KRAS G12C mutation-positive lung cancer, who may lose access to a targeted therapy option. This decision also highlights the challenges pharmaceutical companies face in demonstrating the cost-effectiveness of new treatments to health authorities. The outcome of this decision could influence future drug pricing and reimbursement negotiations, affecting the availability of innovative therapies in the healthcare system. It underscores the ongoing debate over balancing drug costs with clinical benefits in public health funding.
What's Next?
Amgen plans to engage with NICE, the NHS, and other stakeholders to explore options for maintaining access to Lumykras for eligible patients. A consultation on the final draft guidance is open until July 23, allowing for further input from clinicians, patient organizations, and the public. The outcome of this consultation could lead to revised guidance or alternative funding arrangements. The pharmaceutical industry will be closely monitoring this case as it may set a precedent for future drug evaluations and funding decisions.
